VBWG

Data alert

Managing CV Risk in Diabetes: Setting More Aggressive Goals to Meet a Growing Crisis

The evolving diabetes epidemic is raising concern over the adverse long-term effect on cardiovascular (CV) disease.

A Diabetes Outcome Progression Trial

ADOPT

This resource is not available online, you may order a copy of this data alert if it is in stock.

ASCOT: New Insights on Aggressive Risk Factor Intervention to Prevent Major CV Events In Hypertensive Patients

Cardiovascular (CV) disease remains the leading cause of death in the United States, claiming more lives each year than the next four leading causes of death combined.

New ACC/AHA Guidelines: Expanding the Role of Angiotensin Receptor Blockade in Heart Failure with LV Dysfunction

The 2005 ACC/AHA updated guidelines for the treatment of chronic HF and LV dysfunction in adults include an expanded role for ARBs as alternative therapy to ACEIs in selected patients and as added neurohormonal therapy in patients with persistent symptoms who are receiving optimal treatment.

PROactive: The first prospective clinical outcomes trial of PPAR g agonists

Compared with the general population, persons with diabetes have a twofold greater absolute risk of cardiovascular (CV) disease.

HOPE-TOO: Extended use of ACEI reduces CV risk and new diabetes, independent of baseline risk

Results from large clinical trials provide evidence that angiotensin-converting enzyme inhibitors (ACEIs) are effective in the treatment of cardiovascular (CV) disease.

New data on optimal BP lowering in CAD patients: CAMELOT

The results of the Comparison of Amlodipine vs Enalapril to Limit Occurrence of Thrombosis (CAMELOT) study have recently been published.

The INTERHEART Study: New data on global risk

Cardiovascular disease (CVD) is estimated to be the leading cause of mortality and morbidity worldwide.

Expanding opportunities for secondary prevention of stroke

Between 1979 and 2001, the number of patients discharged from the hospital with a primary diagnosis of stroke increased by 25%.

The new mandate for multiple risk reduction

Reducing the morbidity and mortality associated with cardiovascular (CV) disease is becoming as much a public health challenge as it is a research challenge.

Preventing stroke in AF: New data on role of antithrombotic therapy

All forms of atrial fibrillation (AF), whether permanent, persistent, or paroxysmal, are associated with an increased risk of stroke and antithrombotic therapy is recommended for almost all AF patients.

Role of lipid lowering for prevention of cardiovascular events in type 2 diabetes

Cardiovascular (CV) disease is the primary complication and cause of death in people with type 2 diabetes mellitus, 1 accounting for nearly two thirds of deaths.

Blunting the atherosclerotic process in patients with coronary artery disease

Statin therapy lowers serum levels of atherogenic lipoproteins and reduces cardiovascular (CV) morbidity and mortality in a wide range of patients in clinical trials.

Statins and safety: Overview for patient care

Hypercholesterolemia is one of the major modifiable risk factors for coronary heart disease.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

COMET: Results and implications for the treatment of heart failure

Over the course of 25 years, the use of ß-blocking agents to treat heart failure has evolved from a contraindication to an established treatment for mild-to-moderate disease.

ASCOT-LLA: Extending benefits of statins to hypertensive patients

Hypertension and hypercholesterolemia frequently coexist and the interaction of these important risk factors increases cardiovascular risk considerably.

Decrease in PAI-1 antigen is greater with ACE inhibition

Plasminogen activator inhibitor-1 (PAI-1) is a known risk factor for cardiovascular (CV) disease and myocardial infarction (MI).

RITA 3: Benefit of early invasive strategy in moderate-risk unstable angina patients

Final results of RITA 3 (Randomized Intervention Trial of unstable Angina) confirm that an interventional strategy results in a statistically significant reduction in the combined outcome of death, nonfatal myocardial infarction (MI), or refractory angina.

New data on aggressive lipid-lowering management

The results of several recent trials affirm the importance of intensive lipid lowering in at-risk patients.

MERIT-HF: Impact of ß-blocker dose on outcomes in patients with heart failure

In a post hoc subgroup analysis, the MERIT-HF (Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure) researchers examined the relation of ß-blocker dose to clinical outcomes.

HOPE: Effect of long-term therapy with ACE inhibition in high-risk women

Cardiovascular (CV) disease is currently the leading cause of death and the main hospital diagnosis in postmenopausal women.

MERIT-HF: Benefits of ß-blockade in women with heart failure and reduced left ventricular function

Under-representation of women in heart failure (HF) clinical trials has created uncertainty about the efficacy of various treatment strategies in women.

Preventing stroke with ACE inhibition

Each year, approximately 750,000 Americans suffer a first or recurrent stroke.

MIRACL: Very early statin therapy not guided by cholesterol levels is beneficial in acute coronary syndromes

Final results of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial have been published and confirm that treatment with atorvastatin 80 mg/d early during an acute coronary syndrome (ACS) reduces the risk of early recurrent events, primarily recurrent symptomatic ischemia during hospitalization.

SECURE: ACE inhibition retards the progression of atherosclerosis

Final results of the Study to Evaluate Carotid Ultrasound changes with Ramipril and vitamin E (SECURE) have been published and confirm that treatment with ramipril 10 mg slows the progression of atherosclerosis, while treatment with vitamin E has no apparent effect.

Lipids and RAS: Interactions that increase cardiovascular risk

Hypertension and hypercholesterolemia frequently coexist, and over the past decade, provocative data have emerged suggesting the existence of neurohormonal interactions between lipoproteins and the renin-angiotensin system (RAS).

Angiotensin-(1-7): New insights into the benefits of tissue ACE inhibition

Emerging new data are expanding our understanding of the renin-angiotensin system (RAS).

Angiotension type 1 receptor blockade versus ACE inhibition in the treatment of heart failure: Results of 3 clinical trials

Angiotension-converting enzyme (ACE) inhibitors are of critical importance for the treatment of patients with heart failure.

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.

New data on the anti-ischemic effects of ACE inhibition

During the past decade, results from a number of clinical trials have revolutionized the way clinicians treat CHD and CAD.